Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Revance Therapeutic Inc. ($RVNC) announced the results from its US open-label, dose-escalating study assessing DaxibotulinumtoxinA Injectable (RT002) for the treatment of moderate-to-severe isolated cervical dystonia. The company reported that it showed a duration of effect of at least 24 weeks in all three cohorts. At Week 4, RT002 injectable also showed a clinically significant mean reduction of 38% from baseline across all three cohorts.  Revance plans to mull a regulatory path to approval with U.S. and European regulators later this year.
The company stock is currently trading 15 percent up on 12 months basis, while its Year to Date loss stands at 6 percent.

La Jolla Pharmaceutical Company ($LJPC) stock posted 23 percent gain in its previous trading session as the company announced that the data from its phase 3 ATHOS-3 study would be published in  the New England Journal of Medicine. This trial tested the efficacy of LJPC-501 in treating patients with catecholamine-resistant hypotension. The clinical data showed that 70% of patients who used LJPC-501 were able to achieve their target blood pressure. The palcebo grour recorded 23 percent of the patients reaching the target.
La Jolla stock is now up 98 percent on Year to Date basis while its one year gain stands at 126 percent.

 

Avita Medical ($AVMXY) announced positive results from a 30-subject clinical trial evaluating its ReCell device as an adjunct to meshed skin graft in patients with severe burns. The results showed that the use of the device led to the reduction of donor skin required by 30% in comparison to control. The company intends to file a PMA with the FDA by mid-year.
Neuralstem ($CUR) announced completing the dosing of its Phase 2 clinical trial assessing NSI-189 for the treatment of major depressive disorder. The study is 80% powered (p =< 0.05) to show an improvement in depression symptoms versus placebo. It is expected that the top line data will be available in the third quarter. [/toggle] [toggle title=" Approvals" open="yes"] Merck ($MRK) has received the FDA nod for use of its KEYTRUDA (pembrolizumab) in two bladder cancer populations. This includes the first-line treatment of patients with locally advanced/metastatic urothelial carcinoma (UC) who are ineligible for cisplatin-containing chemo and the second-line treatment of patients with advanced/metastatic UC who have progressed during or following platinum-based chemo or within 12 months of neoadjuvant treatment with platinum-containing chemo. Veracyte ($VCYT) announced that Anthem has decided to cover its Afirma Gene Expression Classifier for use in the diagnosis of thyroid cancer for its members. The test is used for identifying patients with benign thyroid nodules whose biopsy results are indeterminate.

 

Diffusion Pharmaceuticals ($DFFN) announced the grant of a patent by the European Patent Office. The patent pertains to its lead product candidate trans sodium crocetinate. The drug candidate is currently being evaluated in a Phase ½ study in newly diagnosed glioblastoma.

United Therapeutics ($UTHR) announced extending its November 2008 exclusive license agreement with Eli Lilly until the end of 2020 subject to conditions. The deal pertains to pulmonary hypertension medication Adcirca (tadalafil).

 

DelMar Pharmaceuticals Inc. ($DMPI) reported its quarterly net loss at $1.8 million or $0.18 per share, up from the net loss of $1.1 million or $0.10 per share it had incurred for the corresponding quarter of the previous year. For the nine months ended March 31, 2017 the Company reported a net loss of $5.48 million or $0.54 per share.

McKesson Corporation ($MCK) reported its revenue for the fourth quarter ended March 31, 2017, at $48.7 billion, up 4% compared to $46.7 billion a year ago.  Its full-year GAAP earnings per diluted share from continuing operations was $23.28 compared to $9.84 a year ago, up 137% year-over-year.

Brokerage
Brokerage Ranking
Action
Company
Rating
Price Target
Impact on Share Price
Jefferies Group LLC
Login to View
Upgrades
athenahealth (ATHN)
Hold
$135.00
Low
Noble Financial
Login to View
Reiterates
Eyegate Pharmaceuticals (EYEG)
Buy

Low

Gainers (% price change)Last TradeChangeMkt CapAchillion PharmaceuticalsACHN4.41+0.63 (16.67%)581.42MCARDIOME PHARMA CORPCRME4.18+0.55 (15.15%)142.02MImmunoGen, Inc.IMGN5.40+0.67 (14.16%)469.58MBioDelivery Sciences IntlBDSI2.30+0.25 (12.20%)133.78MCatalyst PharmaceuticalsCPRX2.22+0.21 (10.45%)177.19MLosers (% price change)Endologix, Inc.ELGX4.26-2.47 (-36.70%)349.84MNewLink Genetics CorpNLNK14.64-1.46 (-9.07%)421.32MDepomed IncDEPO10.20-0.62 (-5.73%)614.85MEndocyte, Inc.ECYT2.66-0.15 (-5.34%)110.23MConcord Medical ServicesCCM4.19-0.19 (-4.34%)183.17MMost Actives (dollar volume)Johnson & JohnsonJNJ126.97+0.24 (0.19%)339.09BShire PLC (ADR)SHPG190.00+7.83 (4.30%)57.00BPfizer Inc.PFE32.22-0.01 (-0.03%)189.70BMerck & Co., Inc.MRK63.89+0.85 (1.35%)172.59BIncyte CorporationINCY128.80+8.31 (6.90%)26.99B